Find Avacopan manufacturers, exporters & distributors on PharmaCompass

PharmaCompass

Synopsis

Synopsis

ACTIVE PHARMA INGREDIENTS

0

CEP/COS

CEP/COS Certifications

0

EU WC

EU WC

0

KDMF

KDMF

0

VMF

NDC API

API REF. PRICE (USD/KG)

MARKET PLACE

0

FDF

0INTERMEDIATES

FINISHED DOSAGE FORMULATIONS

0

Europe

Europe

0

South Africa

South Africa

0

Listed Dossiers

Listed Dossiers

FDF Dossiers

DRUG PRODUCT COMPOSITIONS

REF. STANDARDS OR IMPURITIES

0

EDQM

0

USP

0

JP

0

Others

PATENTS & EXCLUSIVITIES

0

Health Canada Patents

DIGITAL CONTENT

0

Stock Recap #PipelineProspector

0

Weekly News Recap #Phispers

GLOBAL SALES INFORMATION

Finished Drug Prices

NA

0RELATED EXCIPIENT COMPANIES

0EXCIPIENTS BY APPLICATIONS

Chemistry

Click the arrow to open the dropdown
read-moreClick the button for full data set
Also known as: 1346623-17-3, Ccx168, Avacopan [inn], Avacopan [usan], Ccx-168, O880nm097t
Molecular Formula
C33H35F4N3O2
Molecular Weight
581.6  g/mol
InChI Key
PUKBOVABABRILL-YZNIXAGQSA-N
FDA UNII
O880NM097T

Avacopan
Anti-neutrophil cytoplasmic (auto)antibody (ANCA)-associated vasculitis (AAV) is a rare (estimated incidence of 3 cases per 100,000 per year) form of "pauci-immune" systemic small-vessel vasculitis typified by the presence of ANCAs in the serum. The full spectrum of AAV includes granulomatosis with polyangiitis (GPA), microscopic polyangiitis (MPA), eosinophilic granulomatosis with polyangiitis (EGPA), and drug-induced AAV. AAV may be associated with necrotizing and crescentic glomerulonephritis (NCGN). Despite complex pathophysiology, studies over the past ~2 decades have identified a key role for the alternative complement pathway and, in particular, the interaction between the anaphylatoxin fragment C5a and its cognate C5aR receptor in AAV. Avacopan (formerly CCX168) is an allosteric C5aR antagonist indicated for use in AAV. Avacopan was granted FDA approval on October 8, 2021, and is currently marketed under the name TAVNEOS by ChemoCentryx, Inc.
Avacopan is a Complement 5a Receptor Antagonist. The mechanism of action of avacopan is as a Complement 5a Receptor Antagonist, and Cytochrome P450 3A4 Inhibitor.
1 2D Structure

Avacopan

2 Identification
2.1 Computed Descriptors
2.1.1 IUPAC Name
(2R,3S)-2-[4-(cyclopentylamino)phenyl]-1-(2-fluoro-6-methylbenzoyl)-N-[4-methyl-3-(trifluoromethyl)phenyl]piperidine-3-carboxamide
2.1.2 InChI
InChI=1S/C33H35F4N3O2/c1-20-12-15-25(19-27(20)33(35,36)37)39-31(41)26-10-6-18-40(32(42)29-21(2)7-5-11-28(29)34)30(26)22-13-16-24(17-14-22)38-23-8-3-4-9-23/h5,7,11-17,19,23,26,30,38H,3-4,6,8-10,18H2,1-2H3,(H,39,41)/t26-,30-/m0/s1
2.1.3 InChI Key
PUKBOVABABRILL-YZNIXAGQSA-N
2.1.4 Canonical SMILES
CC1=C(C(=CC=C1)F)C(=O)N2CCCC(C2C3=CC=C(C=C3)NC4CCCC4)C(=O)NC5=CC(=C(C=C5)C)C(F)(F)F
2.1.5 Isomeric SMILES
CC1=C(C(=CC=C1)F)C(=O)N2CCC[C@@H]([C@@H]2C3=CC=C(C=C3)NC4CCCC4)C(=O)NC5=CC(=C(C=C5)C)C(F)(F)F
2.2 Other Identifiers
2.2.1 UNII
O880NM097T
2.3 Synonyms
2.3.1 MeSH Synonyms

1. Ccx168

2.3.2 Depositor-Supplied Synonyms

1. 1346623-17-3

2. Ccx168

3. Avacopan [inn]

4. Avacopan [usan]

5. Ccx-168

6. O880nm097t

7. (2r,3s)-2-(4-(cyclopentylamino)phenyl)-1-(2-fluoro-6-methylbenzoyl)-n-(4-methyl-3-(trifluoromethyl)phenyl)piperidine-3-carboxamide

8. (2r,3s)-2-[4-(cyclopentylamino)phenyl]-1-(2-fluoro-6-methylbenzoyl)-n-[4-methyl-3-(trifluoromethyl)phenyl]piperidine-3-carboxamide

9. Tavneos

10. 3-piperidinecarboxamide, 2-(4-(cyclopentylamino)phenyl)-1-(2-fluoro-6-methylbenzoyl)-n-(4-methyl-3-(trifluoromethyl)phenyl)-, (2r,3s)-

11. Ccx168; Avacopan

12. Avacopan [jan]

13. Avacopan [usan:inn]

14. Avacopan [who-dd]

15. Avacopan (jan/usan/inn)

16. Unii-o880nm097t

17. Avacopan [orange Book]

18. Gtpl9450

19. Schembl2567144

20. Chembl3989871

21. C33h35f4n3o2

22. Dtxsid701102660

23. Ex-a2605

24. Mfcd28502293

25. At30195

26. Cs-6888

27. Db15011

28. Ac-35654

29. Hy-17627

30. J3.663.585a

31. D11093

32. Q27285470

33. (2r,3s)-2-[4-(cyclopentylamino)phenyl]-1-(2-fluoro-6-methyl-benzoyl)-n-[4-methyl-3-(trifluoromethyl)phenyl]piperidine-3-carboxamide

34. (2r,3s)-2-[4-(cyclopentylamino)phenyl]-1-(2-fluoro-6-methylbenzene-1-carbonyl)-n-[4-methyl-3-(trifluoromethyl)phenyl]piperidine-3-carboxamide

35. (2r,3s)-2-[4-(cyclopentylamino)phenyl]-1-(2-fluoro-6-methylbenzoyl)-n-[4-methyl-3-(trifluoromethyl)phenyl]-3-piperidinecarboxamide

36. Efd

2.4 Create Date
2011-01-24
3 Chemical and Physical Properties
Molecular Weight 581.6 g/mol
Molecular Formula C33H35F4N3O2
XLogP37.2
Hydrogen Bond Donor Count2
Hydrogen Bond Acceptor Count7
Rotatable Bond Count6
Exact Mass581.26654002 g/mol
Monoisotopic Mass581.26654002 g/mol
Topological Polar Surface Area61.4 Ų
Heavy Atom Count42
Formal Charge0
Complexity918
Isotope Atom Count0
Defined Atom Stereocenter Count2
Undefined Atom Stereocenter Count0
Defined Bond Stereocenter Count0
Undefined Bond Stereocenter Count0
Covalently Bonded Unit Count1
4 Drug and Medication Information
4.1 Drug Indication

Avacopan is indicated for the adjunctive treatment of adult patients with severe active anti-neutrophil cytoplasmic autoantibody (ANCA)-associated vasculitis (granulomatosis with polyangiitis and microscopic polyangiitis; GPA/MPA) in combination with standard therapy including glucocorticoids. Avacopan does not eliminate the need for glucocorticoids.


Tavneos, in combination with a rituximab or cyclophosphamide regimen, is indicated for the treatment of adult patients with severe, active granulomatosis with polyangiitis (GPA) or microscopic polyangiitis (MPA).


5 Pharmacology and Biochemistry
5.1 Pharmacology

Avacopan is a complement 5a receptor (C5aR) antagonist that blocks C5a-induced upregulation of C11b (integrin alpha M) on neutrophils and inhibits C5a-mediated neutrophil activation and migration. Avacopan has been associated with hypersensitivity reactions, including angioedema, and hepatotoxicity, as evidenced by elevated liver transaminases. Likely due to its effect on the complement pathway, avacopan has also been associated with hepatitis B virus reactivation and serious infections, which should be monitored for as appropriate.


5.2 FDA Pharmacological Classification
5.2.1 Active Moiety
AVACOPAN
5.2.2 FDA UNII
O880NM097T
5.2.3 Pharmacological Classes
Mechanisms of Action [MoA] - Cytochrome P450 3A4 Inhibitors
5.3 ATC Code

L04


5.4 Absorption, Distribution and Excretion

Absorption

In AAV patients receiving 30 mg avacopan twice daily, avacopan had a Cmax of 349 169 ng/mL and an AUC0-12hr of 3466 1921 ng\*h/mL. On this dosing scheme, steady-state plasma concentrations are reached by 13 weeks with a roughly 4-fold accumulation. Co-administration of 30 mg with a high-fat meal increased the Cmax by ~8%, the AUC by ~72%, and delayed the Tmax by four hours (from two hours).


Route of Elimination

Avacopan is mainly eliminated in feces, with smaller amounts present in the urine. Following oral administration of the radiolabeled drug, roughly 77% (7% as unchanged avacopan) was recovered in feces while 10% (<0.1% unchanged) was recovered in urine.


Volume of Distribution

Avacopan has an apparent volume of distribution of 345 L.


Clearance

Avacopan has an estimated total apparent body clearance (CL/F) of 16.3 L/h.


5.5 Metabolism/Metabolites

Avacopan is metabolized primarily by CYP3A4. The major circulating M1 metabolite, a mono-hydroxylated form of avacopan, represents ~12% of drug plasma levels and acts as a C5aR antagonist with similar efficacy to avacopan itself.


5.6 Biological Half-Life

A single 30 mg dose of avacopan given with food to healthy subjects resulted in mean elimination half-lives of 97.6 and 55.6 hours for avacopan and its M1 metabolite, respectively.


5.7 Mechanism of Action

Anti-neutrophil cytoplasmic (auto)antibody (ANCA)-associated vasculitis (AAV) is considered a "pauci-immune" form of systemic small-vessel vasculitis accompanied by the presence of ANCAs in the serum. The full spectrum of AAV includes granulomatosis with polyangiitis (GPA), microscopic polyangiitis (MPA), eosinophilic granulomatosis with polyangiitis (EGPA), and drug-induced AAV. AAV may be associated with necrotizing and crescentic glomerulonephritis (NCGN). Of the various known ANCAs, the major antigens are myeloperoxidase (MPO) and proteinase 3 (PR3/myeloblastin). The pathophysiology giving rise to AAV is complex, though a working model has been proposed. An initial trigger, such as infection, causes differentiation of naive T cells into TH17 helper T cells that induce the release from macrophages of pro-inflammatory cytokines (e.g., TNF- and IL-1), which prime neutrophils. Concurrently, the anaphylatoxin C5a is produced through activation of the alternative complement pathway, which also primes neutrophils through binding to the C5a receptor (C5aR; CD88). Primed neutrophils undergo physiological changes, including upregulating the display of ANCA antigens on their surface. Circulating ANCAs bind to displayed ANCA antigens on the surface of neutrophils; simultaneously, the Fc region of these ANCAs is recognized by Fc receptors on other neutrophils, resulting in excessive neutrophil activation. Activated neutrophils form NETs (neutrophil extracellular traps), which induce tissue damage and vasculitis. MPO/PR3 in NETs induces further ANCA production through dendritic cell- and CD4+ T cell-mediated activation of B cells, further exacerbating the condition. A role for complement was not initially considered in AAV due to a lack of excessive complement or immunoglobulin deposition in AAV lesions. However, extensive molecular studies confirmed a significant role for the alternative complement pathway, acting through C3 and C5, in the pathogenesis of AAV. The C5a fragment, generated by C5 cleavage, can bind to both the C5aR and C5a-like receptor (C5L2) on the surface of neutrophils; C5aR binding is associated with AAV while C5L2 binding has a protective effect. As the alternative complement pathway is self-sustaining in the absence of down-regulation by specific proteins, it is likely a significant driver of AAV. Furthermore, neutrophils activated by C5a release reactive oxygen species, properdin, and other molecules that stimulate the complement pathway leading to the production of more C5a in a vicious cycle. Avacopan (CCX168) is a specific C5aR receptor allosteric antagonist that inhibits C5a-mediated neutrophil activation both _in vitro_ and _in vivo_. By inhibiting the C5a/C5aR axis, avacopan should have minimal effects on the formation of the membrane attack complex (which includes C5b) and therefore little effect on the innate immune response in treated patients.


API SUPPLIERS

read-more
read-more

01

Nuray Chemicals Private Limited

India

USDMF, CEP/COS, JDMF, EU-WC, NDC, KDMF, VMF, Others

arrow
Duphat
Not Confirmed
  • fda
  • EDQM
  • WHO-GMP

Virtual BoothNuray is an expert in the synthesis of Niche novel APIs, the first to launch Generics, NCEs, Advanced Intermediates // USFDA certified.

Flag India
Digital Content Digital Content
USDMF CEP/COS JDMF EU-WC NDC arrow-down KDMF VMF Others AUDIT
Nuray Chemicals

02

TAPI Technology & API Services

Israel

USDMF, CEP/COS, JDMF, EU-WC, NDC, KDMF, VMF, Others

  • fda
  • EDQM
  • WHO-GMP

Virtual BoothTAPI offers customized CDMO Solutions for API development and manufacturing services.

Flag Israel
Digital Content Digital Content
USDMF CEP/COS JDMF EU-WC NDC KDMF VMF Others AUDIT
TAPI Company Banner

03

Maithri Drugs

India

USDMF, CEP/COS, JDMF, EU-WC, NDC, KDMF, VMF, Others

Duphat
Not Confirmed
arrow

Maithri Drugs

India

USDMF, CEP/COS, JDMF, EU-WC, NDC, KDMF, VMF, Others

arrow
Duphat
Not Confirmed
USDMF arrow-down CEP/COS JDMF EU-WC NDC KDMF VMF Others AUDIT
blank

04

Hovione

Portugal

USDMF, CEP/COS, JDMF, EU-WC, NDC, KDMF, VMF, Others

Duphat
Not Confirmed
arrow

Hovione

Portugal

USDMF, CEP/COS, JDMF, EU-WC, NDC, KDMF, VMF, Others

arrow
Duphat
Not Confirmed
USDMF CEP/COS JDMF arrow-down EU-WC NDC arrow-down KDMF VMF Others AUDIT
blank
Full Screen ViewFULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results]

JDMF

read-more
read-more

01

Hovione LLC

Portugal
Biotech Showcase
Not Confirmed
arrow

Hovione LLC

Portugal
arrow
Biotech Showcase
Not Confirmed

Avacopan Drug Substance

Registration Number : 303MF10022

Registrant's Address : 40 Lake Drive, East Windsor, NJ08520, USA

Initial Date of Registration : 2021-01-28

Latest Date of Registration : 2021-09-09

blank
Full Screen ViewFULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results]

NDC API

read-more
read-more

01

arrow
BIO Partnering at JPM
Not Confirmed
  • fda
  • EDQM
  • WHO-GMP

Virtual BoothNuray is an expert in the synthesis of Niche novel APIs, the first to launch Generics, NCEs, Advanced Intermediates // USFDA certified.

Flag India
Digital Content Digital Content

AVACOPAN

NDC Package Code : 58159-112

Start Marketing Date : 2024-11-01

End Marketing Date : 2025-12-31

Dosage Form (Strength) : POWDER (35kg/35kg)

Marketing Category : BULK INGREDIENT

Nuray Chemicals

02

Hovione LLC

Portugal
BIO Partnering at JPM
Not Confirmed
arrow

Hovione LLC

Portugal
arrow
BIO Partnering at JPM
Not Confirmed

AVACOPAN

NDC Package Code : 42052-1701

Start Marketing Date : 2021-10-08

End Marketing Date : 2025-12-31

Dosage Form (Strength) : POWDER (1kg/kg)

Marketing Category : BULK INGREDIENT

blank

03

Lonza AG

U.S.A
BIO Partnering at JPM
Not Confirmed
arrow

Lonza AG

U.S.A
arrow
BIO Partnering at JPM
Not Confirmed

AVACOPAN

NDC Package Code : 49187-0834

Start Marketing Date : 2023-02-28

End Marketing Date : 2025-12-31

Dosage Form (Strength) : POWDER (1kg/kg)

Marketing Category : BULK INGREDIENT

blank
Full Screen ViewFULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results]

Listed Suppliers

read-more
read-more

01

arrow
Duphat
Not Confirmed
  • fda
  • EDQM
  • WHO-GMP

Virtual BoothNuray is an expert in the synthesis of Niche novel APIs, the first to launch Generics, NCEs, Advanced Intermediates // USFDA certified.

Flag India
Digital Content Digital Content

Avacopan

About the Company : Established in 2012, Nuray Chemicals Pvt Ltd is an API manufacturer for highly regulated markets. Its manufacturing facility with state-of-the-art R&D is located near Chennai in th...

Established in 2012, Nuray Chemicals Pvt Ltd is an API manufacturer for highly regulated markets. Its manufacturing facility with state-of-the-art R&D is located near Chennai in the Indian state of Tamil Nadu. Nuray’s expertise and experience lie in developing the chemistry requirements of the pharmaceutical industry, including the synthesis of NCEs, impurities, metabolites, method development, advanced intermediates and APIs for commercial launch. With its focus on maintaining the highest levels of quality, reliability and transparency, Nuray has emerged as a trusted partner in the global generic market.
Nuray Chemicals

02

  • fda
  • EDQM
  • WHO-GMP

Virtual BoothTAPI offers customized CDMO Solutions for API development and manufacturing services.

Flag Israel
Digital Content Digital Content

Avacopan

About the Company : Founded in 1935, TAPI Technology & API Services has a long-standing tradition of advancing health through innovation and dedication. Today, we proudly build upon this legacy, drivi...

Founded in 1935, TAPI Technology & API Services has a long-standing tradition of advancing health through innovation and dedication. Today, we proudly build upon this legacy, driving progress in the pharmaceutical industry. Leveraging our extensive experience and world-class expertise, we deliver one of the most comprehensive API portfolios in the industry. Additionally, we provide tailored CDMO services, harnessing our proficiency in diverse technologies to meet our partners' unique needs, ensuring flexibility and excellence in every project.
TAPI Company Banner

03

Duphat
Not Confirmed
arrow
arrow
Duphat
Not Confirmed

Avacopan

About the Company : Maithri Drugs is one of India's fast-growing pharmaceutical companies. Maithri's strategic focus is on active pharma ingredients (APIs). The company is widely recognized for its ex...

Maithri Drugs is one of India's fast-growing pharmaceutical companies. Maithri's strategic focus is on active pharma ingredients (APIs). The company is widely recognized for its excellent research & development and aggressive growth strategies. Our 32 US DMFs and 9 CEPs in a short span attest to our R&D excellence. Maithri's manufacturing facility is located in Hyderabad. This facility is audited and approved by the US FDA. In addition, our facility is certified according to the standards of DCGI, WHO GMP, and ISO 9001:2015 We have a portfolio of 65 products and are continually expanding.
blank
Full Screen ViewFULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results]

API Reference Price

read-more
read-more
[{"dataSource":"API Export","activeIngredients":"","year":"2024","qtr":"Q3","strtotime":1723141800,"product":"FINE ORGANIC COMPOUNDSAVACOPAN NDSRI","address":"BIOCON SEZ, BIOCON PARK,PLOT NO.2 3","city":"N\/A","supplier":"SYNGENE INTERNATIONAL LIMITED","supplierCountry":"INDIA","foreign_port":"TIANJIN","customer":"ASYMCHEM LIFE SCIENCE","customerCountry":"CHINA","quantity":"0.02","actualQuantity":"24","unit":"GMS","unitRateFc":"275.6","totalValueFC":"6532.6","currency":"USD","unitRateINR":22830.974166666667,"date":"09-Aug-2024","totalValueINR":"547943.38","totalValueInUsd":"6532.6","indian_port":"Biocon-SEZ","hs_no":"29420090","bill_no":"3088819","productDescription":"API","marketType":"REGULATED MARKET","country":"CHINA","selfForZScoreResived":"Pharma Grade","supplierPort":"Biocon-SEZ","supplierAddress":"BIOCON SEZ, BIOCON PARK,PLOT NO.2 3, N\/A","customerAddress":""}]
09-Aug-2024
09-Aug-2024
KGS
overview
Loading...

Average Price (USD/KGS)

Number of Transactions

Total Quantity (KGS)

Total Value (USD)

Quantity (KGS) & Unit rate (USD/KGS) over time

API Imports and Exports

Importing Country Total Quantity
(KGS)
Average Price
(USD/KGS)
Number of Transactions

Upgrade, download data, analyse, strategize, subscribe with us contact

Drugs in Development

read-more
read-more

Details:

Tavneos (avacopan) is a complement 5a receptor (C5aR) antagonist that inhibits the interaction between C5aR and the anaphylatoxin C5a, blocking neutrophil activation and migration. Currently being developed for the treatment of ANCA-associated vasculitis.


Lead Product(s): Avacopan,Rituximab

Therapeutic Area: Rare Diseases and Disorders Brand Name: Tavneos

Study Phase: ApprovedProduct Type: Small molecule

Sponsor: Not Applicable

Deal Size: Not Applicable Upfront Cash: Not Applicable

Deal Type: Not Applicable March 28, 2023

blank

01

CSL Vifor

Switzerland
arrow
Duphat
Not Confirmed

CSL Vifor

Switzerland
arrow
Duphat
Not Confirmed

Details : Tavneos (avacopan) is a complement 5a receptor (C5aR) antagonist that inhibits the interaction between C5aR and the anaphylatoxin C5a, blocking neutrophil activation and migration. Currently being developed for the treatment of ANCA-associated vasculitis...

Brand Name : Tavneos

Molecule Type : Small molecule

Upfront Cash : Not Applicable

March 28, 2023

blank

Details:

Tavneos (avacopan) is a complement 5a receptor (C5aR) antagonist that inhibits the interaction between C5aR and the anaphylatoxin C5a, blocking neutrophil activation and migration. Currently being developed for the treatment of ANCA-associated vasculitis.


Lead Product(s): Avacopan,Rituximab

Therapeutic Area: Immunology Brand Name: Tavneos

Study Phase: ApprovedProduct Type: Small molecule

Sponsor: Not Applicable

Deal Size: Not Applicable Upfront Cash: Not Applicable

Deal Type: Not Applicable February 07, 2023

blank

02

CSL Vifor

Switzerland
arrow
Duphat
Not Confirmed

CSL Vifor

Switzerland
arrow
Duphat
Not Confirmed

Details : Tavneos (avacopan) is a complement 5a receptor (C5aR) antagonist that inhibits the interaction between C5aR and the anaphylatoxin C5a, blocking neutrophil activation and migration. Currently being developed for the treatment of ANCA-associated vasculitis...

Brand Name : Tavneos

Molecule Type : Small molecule

Upfront Cash : Not Applicable

February 07, 2023

blank

Details:

The acquisition includes TAVNEOS (avacopan), an orally administered selective complement 5a receptor inhibitor that was approved by the U.S. FDA in October 2021 as an adjunctive therapy for adults with severe active ANCA-associated vasculitis.


Lead Product(s): Avacopan,Rituximab

Therapeutic Area: Immunology Brand Name: Tavneos

Study Phase: ApprovedProduct Type: Small molecule

Sponsor: Amgen Inc

Deal Size: Undisclosed Upfront Cash: Undisclosed

Deal Type: Acquisition October 20, 2022

blank

03

Amgen Inc

U.S.A
arrow
Duphat
Not Confirmed

Amgen Inc

U.S.A
arrow
Duphat
Not Confirmed

Details : The acquisition includes TAVNEOS (avacopan), an orally administered selective complement 5a receptor inhibitor that was approved by the U.S. FDA in October 2021 as an adjunctive therapy for adults with severe active ANCA-associated vasculitis.

Brand Name : Tavneos

Molecule Type : Small molecule

Upfront Cash : Undisclosed

October 20, 2022

blank

Details:

TAVNEOS® (avacopan) is indicated as adjunctive treatment of adult patients with severe active ANCA-associated vasculitis (granulomatosis with polyangiitis) and microscopic polyangiitis [MPA] in combination with standard therapy including glucocorticoids.


Lead Product(s): Avacopan,Rituximab

Therapeutic Area: Immunology Brand Name: Tavneos

Study Phase: ApprovedProduct Type: Small molecule

Sponsor: Not Applicable

Deal Size: Not Applicable Upfront Cash: Not Applicable

Deal Type: Not Applicable August 24, 2022

blank

04

Amgen Inc

U.S.A
arrow
Duphat
Not Confirmed

Amgen Inc

U.S.A
arrow
Duphat
Not Confirmed

Details : TAVNEOS® (avacopan) is indicated as adjunctive treatment of adult patients with severe active ANCA-associated vasculitis (granulomatosis with polyangiitis) and microscopic polyangiitis [MPA] in combination with standard therapy including glucocorticoids...

Brand Name : Tavneos

Molecule Type : Small molecule

Upfront Cash : Not Applicable

August 24, 2022

blank

Details:

Tavneos® (avacopan) is an orally administered small molecule that is a selective inhibitor of the complement C5a receptor C5aR1,reduces the ability of those cells to do damage in response to C5a activation.


Lead Product(s): Avacopan,Rituximab,Cyclophosphamide

Therapeutic Area: Immunology Brand Name: Tavneos

Study Phase: ApprovedProduct Type: Small molecule

Sponsor: Amgen Inc

Deal Size: Not Applicable Upfront Cash: Not Applicable

Deal Type: Not Applicable August 18, 2022

blank

05

CSL Vifor

Switzerland
arrow
Duphat
Not Confirmed

CSL Vifor

Switzerland
arrow
Duphat
Not Confirmed

Details : Tavneos® (avacopan) is an orally administered small molecule that is a selective inhibitor of the complement C5a receptor C5aR1,reduces the ability of those cells to do damage in response to C5a activation.

Brand Name : Tavneos

Molecule Type : Small molecule

Upfront Cash : Not Applicable

August 18, 2022

blank

Details:

The acquisition of ChemoCentryx represents a compelling opportunity for Amgen to add long leadership in inflammation and nephrology with TAVNEOS (avacopan), a first-in-class medicine for patients with serious autoimmune disease, preferably ANCA-associated vasculitis.


Lead Product(s): Avacopan

Therapeutic Area: Immunology Brand Name: Tavneos

Study Phase: ApprovedProduct Type: Small molecule

Sponsor: Amgen Inc

Deal Size: $3,700.0 million Upfront Cash: $3,700.0 million

Deal Type: Acquisition August 04, 2022

blank

06

Amgen Inc

U.S.A
arrow
Duphat
Not Confirmed

Amgen Inc

U.S.A
arrow
Duphat
Not Confirmed

Details : The acquisition of ChemoCentryx represents a compelling opportunity for Amgen to add long leadership in inflammation and nephrology with TAVNEOS (avacopan), a first-in-class medicine for patients with serious autoimmune disease, preferably ANCA-associate...

Brand Name : Tavneos

Molecule Type : Small molecule

Upfront Cash : $3,700.0 million

August 04, 2022

blank

Details:

TAVNEOS® (avacopan), an orally administered selective complement 5a receptor inhibitor, and have potential application in C3 glomerulopathy, as well as the immuno-oncology potential of CCX559, an orally administered small molecule PD-L1 inhibitor.


Lead Product(s): Avacopan,Rituximab

Therapeutic Area: Immunology Brand Name: Tavneos

Study Phase: ApprovedProduct Type: Small molecule

Sponsor: Not Applicable

Deal Size: Not Applicable Upfront Cash: Not Applicable

Deal Type: Not Applicable May 31, 2022

blank

07

Amgen Inc

U.S.A
arrow
Duphat
Not Confirmed

Amgen Inc

U.S.A
arrow
Duphat
Not Confirmed

Details : TAVNEOS® (avacopan), an orally administered selective complement 5a receptor inhibitor, and have potential application in C3 glomerulopathy, as well as the immuno-oncology potential of CCX559, an orally administered small molecule PD-L1 inhibitor.

Brand Name : Tavneos

Molecule Type : Small molecule

Upfront Cash : Not Applicable

May 31, 2022

blank

Details:

The findings support the Company’s plans to advance TAVNEOS® (avacopan) into Phase III development for the treatment of patients with Hurley Stage III (severe) hidradenitis suppurativa.


Lead Product(s): Avacopan

Therapeutic Area: Dermatology Brand Name: Tavneos

Study Phase: Phase IIProduct Type: Small molecule

Sponsor: Not Applicable

Deal Size: Not Applicable Upfront Cash: Not Applicable

Deal Type: Not Applicable May 18, 2022

blank

08

Amgen Inc

U.S.A
arrow
Duphat
Not Confirmed

Amgen Inc

U.S.A
arrow
Duphat
Not Confirmed

Details : The findings support the Company’s plans to advance TAVNEOS® (avacopan) into Phase III development for the treatment of patients with Hurley Stage III (severe) hidradenitis suppurativa.

Brand Name : Tavneos

Molecule Type : Small molecule

Upfront Cash : Not Applicable

May 18, 2022

blank

Details:

Tavneos (avacopan), approved by FDA as an adjunctive treatment of ANCA-associated vasculitis, is a first-in-class, orally administered small molecule that employs a novel, highly targeted mode of action in complement-driven autoimmune and inflammatory diseases.


Lead Product(s): Avacopan,Rituximab

Therapeutic Area: Immunology Brand Name: Tavneos

Study Phase: ApprovedProduct Type: Small molecule

Sponsor: Not Applicable

Deal Size: Not Applicable Upfront Cash: Not Applicable

Deal Type: Not Applicable May 11, 2022

blank

09

Amgen Inc

U.S.A
arrow
Duphat
Not Confirmed

Amgen Inc

U.S.A
arrow
Duphat
Not Confirmed

Details : Tavneos (avacopan), approved by FDA as an adjunctive treatment of ANCA-associated vasculitis, is a first-in-class, orally administered small molecule that employs a novel, highly targeted mode of action in complement-driven autoimmune and inflammatory di...

Brand Name : Tavneos

Molecule Type : Small molecule

Upfront Cash : Not Applicable

May 11, 2022

blank

Details:

EU approval for Tavneos (avacopan) is based on culminating in the results from the pivotal phase-III trial ADVOCATE in 331 patients with ANCA-associated vasculitis also met its primary endpoints of disease remission at week 26 and sustained remission at week 52.


Lead Product(s): Avacopan,Rituximab

Therapeutic Area: Immunology Brand Name: Tavneos

Study Phase: ApprovedProduct Type: Small molecule

Sponsor: Not Applicable

Deal Size: Not Applicable Upfront Cash: Not Applicable

Deal Type: Not Applicable January 19, 2022

blank

10

CSL Vifor

Switzerland
arrow
Duphat
Not Confirmed

CSL Vifor

Switzerland
arrow
Duphat
Not Confirmed

Details : EU approval for Tavneos (avacopan) is based on culminating in the results from the pivotal phase-III trial ADVOCATE in 331 patients with ANCA-associated vasculitis also met its primary endpoints of disease remission at week 26 and sustained remission at ...

Brand Name : Tavneos

Molecule Type : Small molecule

Upfront Cash : Not Applicable

January 19, 2022

blank
click full view
Full Screen ViewFULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results]

Digital Content read-more

Create Content with PharmaCompass, ask us

DATA COMPILATION #PharmaFlow

read-more
read-more

NEWS #PharmaBuzz

read-more
read-more

https://www.ema.europa.eu/en/documents/overview/tavneos-epar-medicine-overview_en.pdf

EMA
19 Jul 2023

https://www.prnewswire.com/news-releases/tavneos-avacopan-included-in-updated-eular-recommendations-for-the-management-of-aav-301782385.html

PR NEWSWIRE
27 Mar 2023

https://www.ema.europa.eu/en/documents/overview/tavneos-epar-medicine-overview_en.pdf

EMA
13 Feb 2023

https://www.ema.europa.eu/en/documents/overview/tavneos-epar-medicine-overview_en.pdf

EMA
25 Nov 2022

https://www.globenewswire.com/news-release/2022/08/24/2503784/19219/en/ChemoCentryx-Announces-TAVNEOS-avacopan-Presentations-at-Upcoming-Medical-Conferences.html

GLOBENEWSWIRE
24 Aug 2022

https://www.businesswire.com/news/home/20220817005538/en

BUSINESSWIRE
17 Aug 2022

Global Sales Information

Do you need Business Intel? Ask us

Market Place

Do you need sourcing support? Ask us

Patents & EXCLUSIVITIES

Check the patents & exclusivity for this product

ABOUT THIS PAGE

Avacopan Manufacturers

A Avacopan manufacturer is defined as any person or entity involved in the manufacture, preparation, processing, compounding or propagation of Avacopan, including repackagers and relabelers. The FDA regulates Avacopan manufacturers to ensure that their products comply with relevant laws and regulations and are safe and effective to use. Avacopan API Manufacturers are required to adhere to Good Manufacturing Practices (GMP) to ensure that their products are consistently manufactured to meet established quality criteria.

click here to find a list of Avacopan manufacturers with USDMF, JDMF, KDMF, CEP, GMP, COA and API Price related information on PhamaCompass.

Avacopan Suppliers

A Avacopan supplier is an individual or a company that provides Avacopan active pharmaceutical ingredient (API) or Avacopan finished formulations upon request. The Avacopan suppliers may include Avacopan API manufacturers, exporters, distributors and traders.

click here to find a list of Avacopan suppliers with USDMF, JDMF, KDMF, CEP, GMP, COA and API Price related information on PharmaCompass.

Avacopan USDMF

A Avacopan DMF (Drug Master File) is a document detailing the whole manufacturing process of Avacopan active pharmaceutical ingredient (API) in detail. Different forms of Avacopan DMFs exist exist since differing nations have different regulations, such as Avacopan USDMF, ASMF (EDMF), JDMF, CDMF, etc.

A Avacopan DMF submitted to regulatory agencies in the US is known as a USDMF. Avacopan USDMF includes data on Avacopan's chemical properties, information on the facilities and procedures used, and details about packaging and storage. The Avacopan USDMF is kept confidential to protect the manufacturer’s intellectual property.

click here to find a list of Avacopan suppliers with USDMF on PharmaCompass.

Avacopan JDMF

The Pharmaceuticals and Medical Devices Agency (PMDA) established the Japan Drug Master File (JDMF), also known as the Master File (MF), to permit Japanese and foreign manufacturers of drug substances, intermediates, excipients, raw materials, and packaging materials (‘Products’) to voluntarily register confidential information about the production and management of their products in Japan.

The Avacopan Drug Master File in Japan (Avacopan JDMF) empowers Avacopan API manufacturers to present comprehensive information (e.g., production methods, data, etc.) to the review authority, i.e., PMDA (Pharmaceuticals & Medical Devices Agency).

PMDA reviews the Avacopan JDMF during the approval evaluation for pharmaceutical products. At the time of Avacopan JDMF registration, PMDA checks if the format is accurate, if the necessary items have been included (application), and if data has been attached.

click here to find a list of Avacopan suppliers with JDMF on PharmaCompass.

Avacopan NDC

National Drug Code is a comprehensive database maintained by the FDA that contains information on all drugs marketed in the US. This directory includes information about finished drug products, unfinished drug products, and compounded drug products, including those containing Avacopan as an active pharmaceutical ingredient (API).

Finished drug products

The FDA updates the NDC directory daily. The NDC numbers for Avacopan API and other APIs are published in this directory by the FDA.

Unfinished drugs

The NDC unfinished drugs database includes product listing information submitted for all unfinished drugs, such as active pharmaceutical ingredients (APIs), drugs intended for further processing and bulk drug substances for compounding.

Pharmaceutical companies that manufacture Avacopan as an active pharmaceutical ingredient (API) must furnish the FDA with an updated record of all drugs that they produce, prepare, propagate, compound, or process for commercial distribution in the US at their facilities.

Compounded drug products

The NDC directory also contains data on finished compounded human drug products that contain Avacopan and are produced by outsourcing facilities. While these outsourcing facilities are not mandated to assign a Avacopan NDC to their finished compounded human drug products, they may choose to do so.

click here to find a list of Avacopan suppliers with NDC on PharmaCompass.

Avacopan GMP

Avacopan Active pharmaceutical ingredient (API) is produced in GMP-certified manufacturing facility.

GMP stands for Good Manufacturing Practices, which is a system used in the pharmaceutical industry to make sure that goods are regularly produced and monitored in accordance with quality standards. The FDA’s current Good Manufacturing Practices requirements are referred to as cGMP or current GMP which indicates that the company follows the most recent GMP specifications. The World Health Organization (WHO) has its own set of GMP guidelines, called the WHO GMP. Different countries can also set their own guidelines for GMP like China (Chinese GMP) or the EU (EU GMP).

PharmaCompass offers a list of Avacopan GMP manufacturers, exporters & distributors, which can be sorted by USDMF, JDMF, KDMF, CEP (COS), WC, API price, and more, enabling you to easily find the right Avacopan GMP manufacturer or Avacopan GMP API supplier for your needs.

Avacopan CoA

A Avacopan CoA (Certificate of Analysis) is a formal document that attests to Avacopan's compliance with Avacopan specifications and serves as a tool for batch-level quality control.

Avacopan CoA mostly includes findings from lab analyses of a specific batch. For each Avacopan CoA document that a company creates, the USFDA specifies specific requirements, such as supplier information, material identification, transportation data, evidence of conformity and signature data.

Avacopan may be tested according to a variety of international standards, such as European Pharmacopoeia (Avacopan EP), Avacopan JP (Japanese Pharmacopeia) and the US Pharmacopoeia (Avacopan USP).

Inform the supplier about your product requirements, specifying if you need a product with particular monograph like EP (Ph. Eur.), USP, JP, BP, or any other quality. In addition, clarify whether you need hydrochloride (HCl), anhydricum, base, micronisatum or a specific level of purity. To find reputable suppliers, utilize the filters and select those certified by GMP, FDA, or any other certification as per your requirement.
For your convenience, we have listed synonyms and CAS numbers to help you find the best supplier. The use of synonyms and CAS numbers can be helpful in identifying potential suppliers, but it is crucial to note that they might not always indicate the exact same product. It is important to confirm the product details with the supplier before making a purchase to ensure that it meets your requirements.
Ask Us for Pharmaceutical Supplier and Partner
Ask Us, Find A Supplier / Partner
No Commissions, No Strings Attached, Get Connected for FREE

What are you looking for?

How can we help you?

The request can't be empty

Please read our Privacy Policy carefully

You must agree to the privacy policy

The name can't be empty
The company can't be empty.
The email can't be empty Please enter a valid email.
The mobile can't be empty